EUVIMEDEUVIMED entdecken
Crossref

Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning

Hanny Al-Samkari, Scott Olitsky, Michael Auerbach

JAMA · 09.11.2026

DOI: 10.1001/jama.2026.21147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, online erschienen am 09.11.2026. Verfasst von Hanny Al-Samkari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses the new US Food and Drug Administration (FDA) boxed warning for intravenous ferric carboxymaltose, how the warning does not go far enough in explaining the potential dangers, and the risks vs benefits of the drug’s use.

Autor:innen und Institutionen

  • Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.
  • Cure HHT, Monkton, Maryland.
  • Georgetown University School of Medicine, Washington, DC.
  • Center for Cancer and Blood Disorders, Baltimore, Maryland.

Zitieren

APA

Al-Samkari, H., Olitsky, S., & Auerbach, M. (2026). Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning. JAMA. https://doi.org/10.1001/jama.2026.21147

Vancouver

Al-Samkari H, Olitsky S, Auerbach M. Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning. JAMA. 2026. doi:10.1001/jama.2026.21147

BibTeX
@article{AlSamkari2026,
  author = {Al-Samkari, Hanny and Olitsky, Scott and Auerbach, Michael},
  title = {Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.21147}
}
Kostenlos starten →